IDEXX Laboratories, Inc. $IDXX Shares Purchased by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS raised its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.1% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 39,600 shares of the company’s stock after buying an additional 1,200 shares during the quarter. KLP Kapitalforvaltning AS’s holdings in IDEXX Laboratories were worth $21,239,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Mutual of America Capital Management LLC raised its stake in IDEXX Laboratories by 79.6% during the first quarter. Mutual of America Capital Management LLC now owns 19,430 shares of the company’s stock valued at $8,160,000 after buying an additional 8,609 shares in the last quarter. Golden State Wealth Management LLC raised its stake in IDEXX Laboratories by 3,766.7% during the first quarter. Golden State Wealth Management LLC now owns 116 shares of the company’s stock valued at $49,000 after buying an additional 113 shares in the last quarter. Plato Investment Management Ltd raised its stake in IDEXX Laboratories by 37.1% during the first quarter. Plato Investment Management Ltd now owns 3,087 shares of the company’s stock valued at $1,310,000 after buying an additional 835 shares in the last quarter. Sagespring Wealth Partners LLC bought a new position in shares of IDEXX Laboratories during the first quarter valued at approximately $229,000. Finally, Genesis Wealth Advisors LLC bought a new position in shares of IDEXX Laboratories during the second quarter valued at approximately $215,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $627.28 on Wednesday. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $688.12. The firm has a market capitalization of $50.18 billion, a price-to-earnings ratio of 52.23, a price-to-earnings-growth ratio of 4.07 and a beta of 1.58. The business has a 50 day simple moving average of $636.83 and a 200 day simple moving average of $538.44. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same period in the prior year, the company posted $2.44 EPS. The business’s revenue for the quarter was up 10.6% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on IDXX shares. Leerink Partners upped their target price on IDEXX Laboratories from $580.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, July 17th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of IDEXX Laboratories in a report on Saturday, September 27th. Stifel Nicolaus set a $640.00 target price on IDEXX Laboratories in a report on Monday, August 4th. UBS Group started coverage on IDEXX Laboratories in a report on Wednesday, October 1st. They set a “neutral” rating and a $720.00 target price for the company. Finally, Jefferies Financial Group started coverage on IDEXX Laboratories in a report on Tuesday, July 1st. They set a “buy” rating and a $625.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $656.50.

Insider Activity

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 7,143 shares of the stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $630.43, for a total transaction of $4,503,161.49. Following the completion of the transaction, the executive vice president directly owned 18,007 shares of the company’s stock, valued at approximately $11,352,153.01. This trade represents a 28.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Michael Lane sold 8,411 shares of the stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $627.74, for a total value of $5,279,921.14. Following the transaction, the executive vice president directly owned 7,132 shares of the company’s stock, valued at approximately $4,477,041.68. The trade was a 54.11% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 54,057 shares of company stock worth $34,293,468 in the last quarter. 0.98% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.